Alpha Cognition (ACOG) Q2 FY26 earnings call

Alpha Cognition reported strong Q2 FY26 results, with Zunveyl demonstrating accelerating commercial traction driven by increased prescriber adoption and nursing home penetration. Despite slower-than-anticipated payer access expansion, the company remains focused on disciplined execution and evidence generation to support Zunveyl's long-term growth and achieve operating profitability in 2027.